Importance of Achieving Disease Control in Adults With Moderate-to-Severe AD
Dermatology
This video features Dr. Eric Simpson's presentation on the importance of achieving disease control in adults with moderate-to-severe AD. Dr. Simpson discusses how adult patients and HCPs talk about disease control and the tools available to help define it. He also explores the roles of IL-4 and IL-13 in the pathophysiology of AD, including how both cytokines promote inflammation and, in turn, contribute to the cumulative burden of the disease. The video concludes with a brief panel discussion.
How type 2 cytokines can amplify inflammatory response in CSU
Dermatology
Dr. Thomos Casale explores the role of Th2 inflammation in CSU, highlighting the impact of IgE autoantibodies and the need for targeted therapies against Th2 cytokines.
Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis
Dermatology
Learn more about how the exaggerated immune response due to chronic and systemic type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis
Type 2 Inflammation: A Common Link Between Atopic Dermatitis and Prurigo Nodularis
Dermatology
In this ADVENT symposium at the 2024 Diversity in Dermatology conference, Dr(s) Sarina Elmariah and Mona Shahriari engage in a dynamic discussion on how clinical signs and itch in atopic dermatitis and prurigo nodularis are impacted by type 2 inflammation.
Under the Skin: Considerations for Atopic Dermatitis and Prurigo Nodularis in Clinical Practice
Dermatology
In this ADVENT symposium at the 2024 Diversity in Dermatology conference, experts Dr(s) Sarina Elmariah and Mona Shahriari engage in a dynamic discussion on diagnostic considerations for atopic dermatitis and prurigo nodularis and how clinical signs and itch in these diseases are impacted by type 2 inflammation.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
All rights reserved. MAT-US-2305040 v3.0-P Exp. Date: 11/24/2025
All Rights Reserved.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.